CALIFORNIA INSTITUTE FOR IMMUNOLOGY AND IMMUNOTHERAPY
California Institute for Immunology and Immunotherapy Will Forge New Era of Discovery and Innovation at the UCLA Research Park
L-R (Founding Donors): Dr. Gary Michelson, Meyer Luskin, Dr. Eric Esrailian, Dr. Arie S. Belldegrun, Michael Milken
A nonprofit public-private partnership in California promises to usher in a new era of biomedical breakthroughs in the fast-growing fields of immunology and immunotherapy — and UCLA’s Vatche and Tamar Manoukian Division of Digestive Diseases will play an active role in the unprecedented effort.
The California Institute for Immunology and Immunotherapy at UCLA (CIII), which capitalizes on UCLA’s strengths in clinical and biomedical research across a range of disciplines, will serve as an anchor tenant at the new UCLA Research Park, located on the site of the former Westside Pavilion shopping mall — the iconic 700,000-square-foot property two miles south of UCLA’s Westwood campus. In that setting, CIII will bring together scholars and industry experts from around the world to create a nexus for discovery and innovation that will benefit Southern California and beyond. Top scientists from UCLA and elsewhere will pursue new tools, treatments, and vaccines for some of the most pressing
health challenges, in digestive diseases as well as other areas of medicine. The acquisition of the UCLA Research Park site was made possible by an intended $500 million investment, with $200 million already allocated, from the State of California to fund the immunology and immunotherapy institute. The CIII is also supported by a group of founding donors from the biotechnology, academic, entrepreneurship, and philanthropic communities led by Meyer Luskin, Dr. Gary Michelson, Dr. Arie S. Belldegrun, Sean Parker, Michael Milken, and Dr. Eric Esrailian, chief of the Vatche and Tamar Manoukian Division of Digestive Diseases.
1
Beyond the Scope
Made with FlippingBook - professional solution for displaying marketing and sales documents online